Maxcyte Share Discussion Threads

[thetrotsky] 18/11/2021 11:52

I made a formal complaint to AJ Bell about the switch from the UK to the US, advising that the spread was not always as important as being able to trade on news (which, given that the UK is still the primary market, generally means that any important news is announced at 7am UK time not 9:30am US time). AJ Bell rejected my complaint but advised that I could still "trade the UK line" during UK maket hours upon request provided that I stated this when calling to place the order. They also advised that I could trade the US line up to 7pm UK time (if not online by telephone). I guess that there will still be FX issues and it's not as easy or covenient as trading online but it's better than nothing.

[edwardt] 17/11/2021 08:14

see that amati sold down near the lows which made me smile.

[assagai] 16/11/2021 21:03

Anyway...on a lighter note, good to see a new month high in the States. Tried hard to get back through 13bucks.

[trident5] 12/11/2021 11:11

Don't understand how, if you bought them on the LSE, you can't sell them on that Exchange. It just sounds like an f/x rip off.

[assagai] 12/11/2021 10:39

Or open an account with Charles Stanley?

[edwardt] 12/11/2021 10:27

that really does suck. sue them!

[lancasterbomber] 12/11/2021 10:09

Big discrepancy betwee States price and UK.Unfortunately AJBell will only trade this on USA market so couldn't add some cheap shares when UK market opened this morning

[edwardt] 11/11/2021 21:46

The US is showing us the lead! I stupidly did not raid my piggy bank. Now where is that hammer?

[adamb1978] 11/11/2021 11:40

I thought the results were pretty decent as was the conference call

The previous revenue guidance was highyl unambitious so not surprising to see it increased at these results, and I think they'll go on to beat the $33m reasonably comfortably too.

The tone of the call was very bullish - investing heavily across the business in R&D and in sales/marketing. They have huge amounts of cash in the bank to be able to fund this though so pleased that they are doing it. I can see losses remaining around current levels for at least another 2-3 years before they start to narrow, which is fine though given that it should drive the revenue upwards faster.

There is no point having a leading technology and growing it conservatively given that all you're doing is providing a window for others to catch-up

For me, this is a buy and hold and am happy to do so for 5-10 years at least

[trident5] 11/11/2021 10:53

Yes, strip out the stock based compensation and the company is losing $1m a month and following two placings has over $250m cash on the balance sheet.

As you say it's about to turn profitable, R&D costs are now falling - so why the need for all that cash?

[assagai] 11/11/2021 10:39

The really worrying trend in these results is that Maxcyte is clearly heading in short order to join that rarefied little club of biotech r&d companies that makes a profit!
This will be terrible news!


For some.....

[nanopayments] 11/11/2021 10:13

I see the resident Debbie Downer is still here! They are ramping the business and hiring a lot of new staff in order to grow sales. That's how businesses scale. How on earth do you expect stock based compensation not to rise? Total revenue increased 41% QoQ whereas operating expenses were only up 8% QoQ. You can try and spin this as a negative all you want, this was a fantastic quarter!

[trident5] 11/11/2021 09:16

Do you think?

Costs growing at some rate even after taking CARMA out.

For the 9 months costs up from $9m to $14m.

And - stock based compensation in the 9 months up from $1.7m to $5.5m.

R&D costs are down.

[shavian] 11/11/2021 08:29

Excellent Q3 results.

[pob69] 04/11/2021 09:23

Trinity Delta new update out - will review TP after Q3 update on 11/11

"...MaxCyte’s proven expertise is increasingly at the heart of the
new generation of gene-edited and cell therapies, which effectively makes
MaxCyte a unique and diversified play on the whole cell engineering field,
providing broad exposure across cell types, technologies, indications, and
approaches."

[adamb1978] 28/10/2021 16:51

Nice announcement.

Previous SPL license announcement was early August
One before that was late May

So coming every 2-3 months. Good for the equity story

[rambutan2] 28/10/2021 14:20

No. 15:

South san francisco and GAITHERSBURG, MD, October 28, 2021 - MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN), a leading provider of enabling platform technologies for ex-vivo cell engineering, today announces the signing of a strategic platform license (SPL) with Nkarta, Inc., a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer.

Under the terms of the agreement, Nkarta obtains non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation(R) technology and ExPERT(TM) platform. In return, MaxCyte is entitled to receive platform licensing fees and program-related milestone payments.

The Nkarta approach maximizes the therapeutic effect of allogeneic NK cells through robust expansion, enhanced targeting and extended persistence resulting in potent immune cells that enable a sustained anti-cancer immune-mediated attack.

"Broad access to the most powerful and promising enabling technologies is critical to our success and the innovation of next-generation NK cell therapies for cancer patients," said Paul J. Hastings, Nkarta's President and CEO. "MaxCyte's electroporation technology leads the field and we're excited to leverage the advantages of their transfection technology with our integrated cell engineering platform ."

Doug Doerfler, President and CEO of MaxCyte, said: "We are proud to support Nkarta's pioneering platform that has the potential to boost the body's immune response to fight cancer. Our team is thrilled to be working with a leader in developing novel products leveraging the unique power of NK cells for the treatment of patients with cancer."

MaxCyte's ExPERT(TM) instrument portfolio is the next generation of leading, clinically-validated, electroporation technology for complex and scalable cell engineering. By delivering high transfection efficiency, seamless scalability and enhanced functionality, the ExPERT(TM) platform delivers the high-end performance essential to enabling the next wave of biological and cellular therapeutics. Nkarta, Inc. is MaxCyte's 15th SPL adding to three MaxCyte partnerships year-to-date, which generate pre-commercial milestone revenue and the vast majority of which include post-commercial revenue.

[spittingbarrel] 20/10/2021 14:42

free stock charts from uk.advfn.com


Double bottom in?

[gsbmba99] 19/10/2021 10:09

If you look at the Vitruvian website, MXCT is listed as one of their current investments The RNS also says "The Vitruvian Investment Partnership III is managed by Vitruvian Partners LLP and is deemed to be the ultimate beneficial owner of Life Tech S.à.r.l." I think what your search was picking up was Life Technologies which is a Thermo owned subsidiary and, coincidentally, where Stark Thompson and Doug Doerfler used to work.

[edwardt] 18/10/2021 15:16

that company that appears to have taken a 3% stake 6/10 rns is the holdco of termo fischer according to my cut and paste in google? if that is right, that is some vindication...

[assagai] 10/10/2021 14:04

Apparently well boosted in the times today but unfortunately the US has control of the reins.

[apad] 10/10/2021 12:01

Ta Trotsky.
apad

[thetrotsky] 10/10/2021 08:52

Apad, Did you mean GKN or did you mean GSK?

[apad] 09/10/2021 17:23

Fairly obvious reactions from the tintins, davep4.
Not a criticism for posting, your biopharmadive link was an excellent precis.
A friend worked for GSK back in the heyday and said that nobody outside the company knew anything about what was really going on in drug development

I agree with the earlier comment about the lack of a "read across" to other trials. However the Allogene trial may be more important than I had realised.

FDA approval is a bit like waiting for drill results from an O&G explorer. 😊

apad